Literature DB >> 18627399

Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization.

R B G Azeredo-Coutinho1, D C S Matos, G G R Armôa, R M Maia, A Schubach, W Mayrink, S C F Mendonça.   

Abstract

It is known that the same antigen can induce different immune responses, depending upon the way that it is presented to the immune system. The objective of this study was to compare cytokine responses of peripheral blood mononuclear cells (PBMC) from cutaneous leishmaniasis patients and subjects immunized with a first-generation candidate vaccine composed of killed Leishmania amazonensis promastigotes to a whole-cell promastigote antigen extract (La) and to the recombinant protein LACK (Leishmania analogue receptor for activated C kinase), both from L. amazonensis. Thirty-two patients, 35 vaccinees and 13 healthy subjects without exposure to Leishmania, were studied. Cytokine production was assessed by enzyme-linked immunosorbent assay and enzyme-linked immunospot assay. The interferon (IFN)-gamma levels stimulated by La were significantly higher and the levels of interleukin (IL)-10 significantly lower than those stimulated by LACK in the patient group, while LACK induced a significantly higher IFN-gamma production and a significantly lower IL-10 production compared with those induced by La in the vaccinated group. LACK also induced a significantly higher frequency of IFN-gamma-producing cells than did La in the vaccinated group. The contrast in the cytokine responses stimulated by LACK and La in PBMC cultures from vaccinated subjects versus patients indicates that the human immune response to crude and defined Leishmania antigens as a consequence of immunization differs from that induced by natural infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627399      PMCID: PMC2527360          DOI: 10.1111/j.1365-2249.2008.03705.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Leishmaniasis.

Authors:  Philippe Desjeux
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633

2.  IFN-gamma-producing CD45RA+CD8+ and IL-10-producing CD45RA-CD4+ T cells generated in response to LACK in naive subjects never exposed to Leishmania.

Authors:  Eliane Bourreau; Marion Collet; Ghislaine Prévot; Geneviève Milon; Dominique Ashimoff; Hitoshi Hasagewa; Carlos Parra-Lopez; Pascal Launois
Journal:  Eur J Immunol       Date:  2002-02       Impact factor: 5.532

3.  Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets.

Authors:  R M Locksley; F P Heinzel; M D Sadick; B J Holaday; K D Gardner
Journal:  Ann Inst Pasteur Immunol       Date:  1987 Sep-Oct

4.  Up-regulation of Th1-type responses in mucosal leishmaniasis patients.

Authors:  Olívia Bacellar; Hélio Lessa; Albert Schriefer; Paulo Machado; Amélia Ribeiro de Jesus; Walderez O Dutra; Kenneth J Gollob; Edgar M Carvalho
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63).

Authors:  S C Mendonça; D G Russell; S G Coutinho
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

6.  Characterization of the immune response to Leishmania infantum recombinant antigens.

Authors:  Lucas Pedreira de Carvalho; Manuel Soto; Selma Jerônimo; Blaise Dondji; Olívia Bacellar; Viviane Luz; Glória Orge Orge; Carlos Alonso; Amélia R Jesus; Edgar M Carvalho
Journal:  Microbes Infect       Date:  2003-01       Impact factor: 2.700

7.  A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis.

Authors:  P M De Luca; W Mayrink; J A Pinto; S G Coutinho; M A Santiago; V P Toledo; C A Costa; O Genaro; A B Reis; S C Mendonça
Journal:  Acta Trop       Date:  2001-12-21       Impact factor: 3.112

8.  Human american cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy.

Authors:  S C Mendonça; S G Coutinho; R R Amendoeira; M C Marzochi; C Pirmez
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Leishmania major LACK antigen is required for efficient vertebrate parasitization.

Authors:  Ben L Kelly; Daniel B Stetson; Richard M Locksley
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more
  6 in total

1.  Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.

Authors:  A B B Macedo; J C Sánchez-Arcila; A O Schubach; S C F Mendonça; A Marins-Dos-Santos; M de Fatima Madeira; T Gagini; M I F Pimentel; P M De Luca
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

2.  Cellular and humoral responses to Leishmania major virulence factors in healed cutaneous leishmaniasis and Mediterranean visceral leishmaniasis patients.

Authors:  Inès Lakhal-Naouar; Thouraya Boussoffara; Amel Meddeb-Garnaoui; Yosser Ben Achour-Chenik; Hechmi Louzir; Mehdi Chenik
Journal:  Clin Vaccine Immunol       Date:  2009-04-01

3.  Leishmania infantum Virulence Factor A2 Protein: Linear B-Cell Epitope Mapping and Identification of Three Main Linear B-Cell Epitopes in Vaccinated and Naturally Infected Dogs.

Authors:  Monique Paiva Campos; Fabiano Borges Figueiredo; Fernanda Nazaré Morgado; Alinne Rangel Dos Santos Renzetti; Sara Maria Marques de Souza; Sandro Antônio Pereira; Rodrigo Nunes Rodrigues-Da-Silva; Josué Da Costa Lima-Junior; Paula Mello De Luca
Journal:  Front Immunol       Date:  2018-07-25       Impact factor: 7.561

4.  Ultradeformable Archaeosomes for Needle Free Nanovaccination with Leishmania braziliensis Antigens.

Authors:  Leticia H Higa; Laura Arnal; Mónica Vermeulen; Ana Paula Perez; Priscila Schilrreff; Cecilia Mundiña-Weilenmann; Osvaldo Yantorno; María Elena Vela; María José Morilla; Eder Lilia Romero
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

Review 5.  Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery.

Authors:  Sergio C F Mendonça
Journal:  Parasit Vectors       Date:  2016-09-06       Impact factor: 3.876

6.  Antigenicity of Leishmania-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters.

Authors:  Laura Fernández; Eugenia Carrillo; Lucas Sánchez-Sampedro; Carmen Sánchez; Ana Victoria Ibarra-Meneses; M Angeles Jimenez; Valter Dos Anjos Almeida; Mariano Esteban; Javier Moreno
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.